208 related articles for article (PubMed ID: 31601421)
1. Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria).
Lefebvre T; Millot S; Richard E; Blouin JM; Lalanne M; Lamrissi-Garcia I; Costet P; Lyoumi S; Gouya L; Puy H; Moreau-Gaudry F; de Verneuil H; Karim Z; Ged C
Biochem Biophys Res Commun; 2019 Dec; 520(2):297-303. PubMed ID: 31601421
[TBL] [Abstract][Full Text] [Related]
2. Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.
Blouin JM; Ged C; Lalanne M; Lamrissi-Garcia I; Morice-Picard F; Costet P; Daher R; Moreau-Gaudry F; Bedel A; Puy H; Gouya L; Karim Z; Richard E
Blood; 2020 Nov; 136(21):2457-2468. PubMed ID: 32678895
[TBL] [Abstract][Full Text] [Related]
3. Hemolytic anemia repressed hepcidin level without hepatocyte iron overload: lesson from Günther disease model.
Millot S; Delaby C; Moulouel B; Lefebvre T; Pilard N; Ducrot N; Ged C; Lettéron P; de Franceschi L; Deybach JC; Beaumont C; Gouya L; De Verneuil H; Lyoumi S; Puy H; Karim Z
Haematologica; 2017 Feb; 102(2):260-270. PubMed ID: 28143953
[TBL] [Abstract][Full Text] [Related]
4. Advances in understanding the pathogenesis of congenital erythropoietic porphyria.
Di Pierro E; Brancaleoni V; Granata F
Br J Haematol; 2016 May; 173(3):365-79. PubMed ID: 26969896
[TBL] [Abstract][Full Text] [Related]
5. A knock-in mouse model of congenital erythropoietic porphyria.
Ged C; Mendez M; Robert E; Lalanne M; Lamrissi-Garcia I; Costet P; Daniel JY; Dubus P; Mazurier F; Moreau-Gaudry F; de Verneuil H
Genomics; 2006 Jan; 87(1):84-92. PubMed ID: 16314073
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria.
Blouin JM; Duchartre Y; Costet P; Lalanne M; Ged C; Lain A; Millet O; de Verneuil H; Richard E
Proc Natl Acad Sci U S A; 2013 Nov; 110(45):18238-43. PubMed ID: 24145442
[TBL] [Abstract][Full Text] [Related]
7. Iron and hepcidin: a story of recycling and balance.
Camaschella C
Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154
[TBL] [Abstract][Full Text] [Related]
8. ALAS2 acts as a modifier gene in patients with congenital erythropoietic porphyria.
To-Figueras J; Ducamp S; Clayton J; Badenas C; Delaby C; Ged C; Lyoumi S; Gouya L; de Verneuil H; Beaumont C; Ferreira GC; Deybach JC; Herrero C; Puy H
Blood; 2011 Aug; 118(6):1443-51. PubMed ID: 21653323
[TBL] [Abstract][Full Text] [Related]
9. Congenital erythropoietic porphyria: characterization of murine models of the severe common (C73R/C73R) and later-onset genotypes.
Bishop DF; Clavero S; Mohandas N; Desnick RJ
Mol Med; 2011; 17(7-8):748-56. PubMed ID: 21365124
[TBL] [Abstract][Full Text] [Related]
10. Missense UROS mutations causing congenital erythropoietic porphyria reduce UROS homeostasis that can be rescued by proteasome inhibition.
Blouin JM; Bernardo-Seisdedos G; Sasso E; Esteve J; Ged C; Lalanne M; Sanz-Parra A; Urquiza P; de Verneuil H; Millet O; Richard E
Hum Mol Genet; 2017 Apr; 26(8):1565-1576. PubMed ID: 28334762
[TBL] [Abstract][Full Text] [Related]
11. Interdependence between degree of porphyrin excess and disease severity in congenital erythropoietic porphyria (Günther's disease).
Freesemann AG; Bhutani LK; Jacob K; Doss MO
Arch Dermatol Res; 1997 Apr; 289(5):272-6. PubMed ID: 9164637
[TBL] [Abstract][Full Text] [Related]
12. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.
Robert-Richard E; Moreau-Gaudry F; Lalanne M; Lamrissi-Garcia I; Cario-André M; Guyonnet-Dupérat V; Taine L; Ged C; de Verneuil H
Am J Hum Genet; 2008 Jan; 82(1):113-24. PubMed ID: 18179890
[TBL] [Abstract][Full Text] [Related]
13. Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.
Bishop DF; Johansson A; Phelps R; Shady AA; Ramirez MC; Yasuda M; Caro A; Desnick RJ
Am J Hum Genet; 2006 Apr; 78(4):645-58. PubMed ID: 16532394
[TBL] [Abstract][Full Text] [Related]
14. [Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure].
de Verneuil H; Moreau-Gaudry F; Ged C; Bensidhoum M; Hombrados I; Tricoire J; Rolland M
Arch Pediatr; 1995 Aug; 2(8):755-61. PubMed ID: 7550841
[TBL] [Abstract][Full Text] [Related]
15. Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells.
Kauppinen R; Glass IA; Aizencang G; Astrin KH; Atweh GF; Desnick RJ
Mol Genet Metab; 1998 Sep; 65(1):10-7. PubMed ID: 9787090
[TBL] [Abstract][Full Text] [Related]
16. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload.
Altamura S; Kessler R; Gröne HJ; Gretz N; Hentze MW; Galy B; Muckenthaler MU
Cell Metab; 2014 Aug; 20(2):359-67. PubMed ID: 25100063
[TBL] [Abstract][Full Text] [Related]
17. Congenital erythropoietic porphyria: Recent advances.
Erwin AL; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):288-297. PubMed ID: 30685241
[TBL] [Abstract][Full Text] [Related]
18. The molecular basis of iron overload disorders and iron-linked anemias.
Kaplan J; Ward DM; De Domenico I
Int J Hematol; 2011 Jan; 93(1):14-20. PubMed ID: 21210258
[TBL] [Abstract][Full Text] [Related]
19. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
[TBL] [Abstract][Full Text] [Related]
20. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis.
Vokurka M; Krijt J; Sulc K; Necas E
Physiol Res; 2006; 55(6):667-674. PubMed ID: 16497104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
